Bethel College athletes hosted a cheek swab drive Wednesday and continued Thursday evening. It's all to find a bone marrow ...

The trial was designed to evaluate the therapy’s efficacy and safety in treating AML, as well as myelodysplastic syndromes.

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Among patients with acute myeloid leukemia (AML) in remission following second-line salvage therapy, the immunotherapeutic agent galinpepimut-S (GPS) demonstrated preliminary signals of efficacy and ...

TCR-α/β and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma ... refractory B-cell acute lymphoblastic leukemia ...

Citation Format: Alessandra Perini, Marti Brucoli, Sophie Acton, Luigi Ombrato. Understanding myeloid and lymphoid cell heterogeneity following radiotherapy and its impact on metastasis development in ...

Lymphomas, lymphocytic leukemias, and myeloma are from the lymphoid line, while acute and chronic myelogenous leukemia, myelodysplastic syndromes and myeloproliferative diseases are myeloid in origin.